Source comparison
Melanocortin Receptor Selectivity vs Growth Hormone Pathway Peptides
Melanotan-1 binds melanocortin receptors MC1R (expressed primarily in melanocytes and keratinocytes) and MC4R (expressed in hypothalamic neurons regulating energy balance and sexual function). Growth hormone peptides. GHRP-2, GHRP-6, ipamorelin, CJC-1295, and
This comparison does not assign a generated winner or score.
- Melanotan-1 binds melanocortin receptors MC1R (expressed primarily in melanocytes and keratinocytes) and MC4R (expressed in hypothalamic neurons regulating energy balance and sexual function). Growth hormone peptides. GHRP-2, GHRP-6, ipamorelin, CJC-1295, and MK 677. Act on growth hormone secretagogue receptors (GHSR, also called ghrelin receptors) in the anterior pituitary and arcuate nucleus. These are entirely separate receptor families with zero structural overlap.
- Growth hormone peptides stimulate pulsatile GH release, which downstream increases IGF-1 (insulin-like growth factor-1) production in the liver. That IGF-1 elevation drives anabolic signaling in muscle tissue, bone remodeling, lipolysis in adipose tissue, and collagen synthesis. Melanotan-1 does not interact with GHSR, does not stimulate GH secretion, and produces no measurable IGF-1 elevation. Meaning researchers investigating growth, recovery, or body composition changes will see zero activity from melanotan-1 in those pathways.
- Conversely, melanotan-1's MC1R activation increases eumelanin synthesis in melanocytes. The mechanism underlying its primary research use in photoprotection and pigmentation studies. Growth hormone peptides have no melanocortin receptor activity and produce no pigmentation changes regardless of dose or duration. A 12-week study published in JAMA Dermatology demonstrated that subcutaneous afamelanotide (melanotan-1's pharmaceutical name) increased constitutive pigmentation by 3–5 Fitzpatrick scale units in fair-skinned subjects, while concurrent growth hormone administration produced no measurable pigmentation effect.
- Our experience working with researchers transitioning between peptide protocols: the most common error is assuming 'peptides are interchangeable if the goal is similar.' A researcher investigating metabolic optimization who substitutes melanotan-1 for a GLP-1 agonist because both 'affect weight' will fail. The mechanisms and outcomes are unrelated despite superficial marketing overlap.